Wednesday, February 25th 11:00-12:15pm ET
A Conversation with Tim Opler
Aging: Looking Forward
Aging biology has reached a true inflection point—scientifically, clinically, and commercially—and is now ready for serious drug development and investment. Tim challenges the view that aging is too complex or unapproachable, as he outlines credible regulatory and trial pathways, and makes the case that targeting the root causes of aging could unlock a trillion-dollar market while reducing disease and healthcare costs. In short, aging is no longer fringe science — it’s the next major opportunity in biopharma.
This discussion is part two of a two-part series on aging. Part one reviewed the history of aging research (and can be watched here). These salons are based on two Stifel reports Tim Opler authored in 2025.
*BIOTECHGATE DIGITAL PARTNERING: All virtual salon participants receive complimentary access to one week of virtual partnering with 1000+ participants from all around the globe during Biotechgate's Digital Partnering event. LEARN MORE